07:35:48 EDT Fri 29 Mar 2024
Enter Symbol
or Name
USA
CA



Veritas Pharma Inc
Symbol VRT
Shares Issued 38,714,590
Close 2017-11-29 C$ 0.81
Market Cap C$ 31,358,818
Recent Sedar Documents

Veritas Pharma appoints Dawson to advisory board

2017-11-29 16:40 ET - News Release

Dr. Lui Franciosi reports

VERITAS PHARMA APPOINTS OF BC'S "TOP 40 UNDER 40" ROBERT DAWSON -- HIGHLY REGARDED MARKETING & INNOVATION EXPERT TO ITS ADVISORY BOARD

Veritas Pharma Inc. has appointed Robert (Rob) Dawson to its advisory board. Mr. Dawson is a highly regarded expert in marketing and innovation with a wealth of experience in business leadership, go-to-market strategy, branding and technology.

Mr. Dawson is a performance-driven and innovative executive with over 20 years of global experience in business leadership, strategic marketing, consulting, technology, crowd sourcing, innovation and communications. He is currently president and chief executive officer of Tectonic Strategy Inc., a boutique innovation and business model advisory firm for technology companies.

As a C-level executive in growing software technology and innovation companies, Mr. Dawson has developed and delivered compelling business strategies for both Fortune 500 and growing enterprises. His experience crosses several categories, including technology, financial services, blockchain, consumer goods, food, retail and environmental sustainability, with well-known brands such as Intel, Dell, LG Electronics, Microsoft, Expedia, HSBC, Lego, Velcro and others. He has extensive experience in the ideation and creation of new technology-based business models based on emerging market dynamics.

Mr. Dawson has held positions as chief client officer at Better Ventures and chief marketing officer at Chaordix, a crowd-sourcing software-as-a-service (SaaS) company. He holds a bachelor of commerce from Queen's University. A frequent speaker at global marketing and innovation events, Mr. Dawson was president of the Association of Integrated Marketers (AIM) and a member of the Digital Strategy Conference advisory board; in 2006, he was recognized as one of British Columbia's Top 40 Under 40.

Veritas's chief executive officer, Dr. Lui Franciosi, remarked: "As we draw closer to commercialization of our patented cannabis strains, it is important that we develop compelling go-to-market strategies. Mr. Dawson's expertise in this area will be highly valuable to Veritas. We will be soon competing in the multibillion-dollar Canadian market as well as in other countries where medical cannabis is legal. We want to make ensure that we got his expertise to help us differentiate our products and develop compelling value propositions for the target markets."

From the Canadian perspective, the current total market for cannabis is estimated at $5-billion, of which approximately 20 per cent is medical (CIBC World Markets, 2016). Legalization of cannabis in Canada is projected to increase the market size and open new opportunities for cannabis products.

About Veritas Pharma Inc.

Veritas Pharma is an emerging-stage pharmaceutical and IP (intellectual property) development company that, through its 80-per-cent-owned Cannevert Therapeutics Ltd. (CTL), is advancing the science behind medical cannabis. It is the company's aim, through its investment in CTL, to develop the most effective cannabis strains (cultivars) specific to pain, nausea, epilepsy and PTSD (posttraumatic stress disorder), solving the critical need for clinical data to support medical marijuana claims.

© 2024 Canjex Publishing Ltd. All rights reserved.